The Growth Hormone System

Growth hormone (GH) is a 191-amino-acid peptide hormone produced by the anterior pituitary gland. It is released in pulsatile bursts, with the largest pulse occurring during deep (stage 3/4) sleep. GH does not act directly on most tissues. Instead, it stimulates the liver to produce IGF-1 (insulin-like growth factor 1), which mediates most of GH's anabolic effects: muscle protein synthesis, bone density maintenance, fat oxidation, and cellular repair. GH production peaks during adolescence and declines steadily thereafter, dropping approximately 14% per decade after age 30.

The GH axis is regulated by two hypothalamic hormones: GHRH (growth hormone-releasing hormone), which stimulates GH release, and somatostatin, which inhibits it. This dual-control system creates the pulsatile release pattern. GH secretagogues work by either mimicking GHRH to stimulate release, inhibiting somatostatin to remove the brake, or stimulating ghrelin receptors (GHRPs) that independently trigger GH secretion. Understanding this regulatory system is essential for designing protocols that enhance GH output without disrupting the natural pulsatile pattern.

The goal of GH optimization through peptides is not to replace your body's GH production but to amplify it. This is fundamentally different from exogenous GH injection, which delivers a flat dose of synthetic GH and can suppress your own production through negative feedback. GH secretagogues stimulate your pituitary to produce and release more of your own GH, maintaining the natural pulsatile pattern that tissues respond to most effectively. This approach produces the benefits of elevated GH (improved body composition, faster recovery, better sleep, enhanced skin quality) with a significantly better safety profile than exogenous GH.